4//SEC Filing
Tarriff Scott 4
Accession 0001209191-23-029625
CIK 0000827871other
Filed
May 14, 8:00 PM ET
Accepted
May 15, 8:34 PM ET
Size
12.2 KB
Accession
0001209191-23-029625
Insider Transaction Report
Form 4
Tarriff Scott
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-05-11$20.71/sh−15,000$310,650→ 1,624,934 total - Sale
Common Stock
2023-05-12$19.69/sh−3,131$61,649→ 1,621,803 total - Sale
Common Stock
2023-05-12$20.42/sh−11,869$242,365→ 1,609,934 total - Sale
Common Stock
2023-05-15$21.06/sh−14,800$311,688→ 1,595,134 total - Sale
Common Stock
2023-05-15$21.52/sh−200$4,304→ 1,594,934 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $20.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5).
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $20.11 inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.745 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.4867 to $21.43 inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.525 inclusive.
Documents
Issuer
EAGLE PHARMACEUTICALS, INC.
CIK 0000827871
Entity typeother
Related Parties
1- filerCIK 0001469124
Filing Metadata
- Form type
- 4
- Filed
- May 14, 8:00 PM ET
- Accepted
- May 15, 8:34 PM ET
- Size
- 12.2 KB